前收市價 | 0.0100 |
開市 | 0.0100 |
買盤 | 0.0000 |
賣出價 | 2.1200 |
拍板 | 335.00 |
到期日 | 2024-05-31 |
今日波幅 | 0.0100 - 0.0100 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 18 |
There's probably a big enough pie here for everyone to get a slice.
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
The Amgen of 2027 could be much be larger than some investors expect.